1132941-95-7

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 503315-74-0 (3-fluoro-4-nitrophenyl)methanol 
• 131858-37-2 4-(bromomethyl)-2-fluoro-1-nitrobenzene 
• 122-52-1 triethyl phosphite 

Downstream Products

• 1132936-92-5 (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)-2-fluorophenyl)methanesulfonamidede 
• 1299487-72-1 1-(2-amino-2-methylpropyl)-3-(2-fluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)urea 
• 1299487-71-0 2-(4-((4-(4-aminobenzylidene)piperidin-1-yl)methyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1299487-70-9 tert-butyl 4-(4-aminobenzylidene)piperidine-1-carboxylate 
• 1299487-68-5 4-(piperidin-4-ylidenemethyl)aniline 
• 1299487-67-4 1-(4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-ylidene)methyl)phenyl)-3-(2-hydroxy-2-methylpropyl)urea 
• 1299488-12-2 1-(2-amino-2-methylpropyl)-3-(2-fluoro-4-(piperidin-4-ylmethyl)phenyl)urea 
• 1299488-11-1 tert-butyl 4-(4-(3-(2-amino-2-methylpropyl)ureido)-3-fluorobenzyl)piperidine-1-carboxylate 
• 1299488-10-0 1-(2-amino-2-methylpropyl)-3-(2-fluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-propylbenzyl)piperidin-4-yl)methyl)phenyl)urea 
• 1299488-08-6 1-(2-fluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)-3-(pyridin-4-yl)urea 
• 1299487-73-2 2-(4-((4-(4-amino-3-fluorobenzyl)piperidin-1-yl)methyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1299487-75-4 2-fluoro-4-(piperidin-4-ylmethyl)aniline 
• 1299487-74-3 tert-butyl 4-(4-amino-3-fluorobenzyl)piperidine-1-carboxylate 
• 1299487-69-6 tert-butyl 4-(3-fluoro-4-nitrobenzylidene)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to impr

(1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS

The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl

N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such interm